Virus injection targets liver tumors in early trial
NCT ID NCT00629759
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The study focused on safety and immune response, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dong-A University Hospital
Busan, 602-715, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New registry aims to sharpen liver tumor ablation techniques
- New blood test could end guesswork in liver cancer diagnosis
- Scientists peer into liver cancer cells to unlock secrets
- Thousands of surgery patients studied to uncover hidden voice box injuries
- Exercise program aims to boost liver transplant recovery